Curated News
By: NewsRamp Editorial Staff
July 02, 2026

Bora Buys MacroGenics' GMP Ops for $122.5M, Boosts US Biologics Capacity

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Bora Pharmaceuticals' $122.5M acquisition of MacroGenics' facility gives clients US-based, inspection-proven biologics manufacturing capacity.
  • The acquisition adds 20,000 liters of single-use bioreactor capacity across two US sites and one Taiwan facility for end-to-end biologics.
  • Bora's US biologics platform reduces offshore dependency, enabling faster access to medicines for patients globally.
  • Bora's Rockville site has passed five FDA inspections and supports over 120 GMP batches for global markets.

Impact - Why it Matters

This acquisition matters because it strengthens US-based biologics manufacturing capacity, reducing reliance on offshore production. For biotech and pharma companies, it offers a proven, FDA-inspected platform for developing and commercializing biologics and biosimilars, potentially lowering supply chain risks and accelerating time to market. As regulatory dynamics evolve, having a domestic manufacturing partner becomes crucial for ensuring stable supply and compliance.

Summary

Bora Pharmaceuticals Co., Ltd. has completed its acquisition of MacroGenics' GMP manufacturing operations for $122.5 million, establishing a 20,000-liter US biologics drug substance manufacturing platform. The deal includes the Rockville, Maryland biologics drug substance facility and a warehousing center in Frederick, Maryland. Bora signed a long-term CDMO Service Agreement with MacroGenics upon closing. This acquisition, announced via Media OutReach Newswire, integrates Bora Biologics' capabilities across two US sites and one in Taiwan, offering end-to-end services from development to commercial supply.

Bora Group Chairman and CEO Bobby Sheng emphasized that the platform provides a reliable, US-based manufacturing solution for biotech and pharmaceutical companies amid evolving regulatory and supply chain dynamics. The Rockville addition brings Bora Biologics' active commercial programs to over four, with more than 120 completed GMP batches supplying markets including the US, EU, Japan, Canada, and the UK. The combined network has passed five FDA inspections and one PMDA review, supporting over 33 biologics and 15 biosimilars. Bora plans to integrate its US drug substance capabilities with sterile drug product capabilities over the next 12-18 months, creating a seamless biologics solution.

Bora Pharmaceuticals, founded in 2007, operates under a "Dual Engine" model combining CDMO and commercial expertise. The company focuses on niche and rare disease markets, investing in talent and infrastructure to achieve sustainable growth. This acquisition marks a significant step in reducing offshore dependency for biologics manufacturing, providing a domestically anchored infrastructure for clients. With the new capacity, Bora Biologics is poised to meet growing demand for US-based manufacturing, offering sponsors a fully integrated platform from development to licensed commercial supply.

Source Statement

This curated news summary relied on content disributed by Media Outreach. Read the original source here, Bora Buys MacroGenics' GMP Ops for $122.5M, Boosts US Biologics Capacity

blockchain registration record for this content.